Slayback Pharma announces approval and immediate launch of Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection in 200 mcg/ 50 mL and 400 mcg/ 100 mL (4 mcg/mL) vials, generic equivalent of Precedex™ 4 mcg/ mL

PRINCETON, N.J., Dec. 10, 2019 /PRNewswire/ --Slayback Pharma LLC announced today the final approval and launch in the United States of Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection.